TMCnet News
Pharm-Olam International Expands to Larger Facility in PolandPharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization (CRO) to biopharmaceutical and device industries, is proud to announce the relocation of its Polish location to a larger office to accommodate for its growing staff. "We have seen a significant increase in interest in running trials in Poland and we are expanding our offices to accommodate the current and future workload," explained Sanjiv Suri, Chief Executive Officer (USA). "When we opened our first operating office in Poland in 1995, we had to convince potential sponsors to place their trials in this emerging country. Nowadays, Poland is near the top of the list of countries that sponsors know can produce high quality data, on time. Our staff numbers in Poland has increased over the past few years and we anticipate a 25% growth of our staff in Poland to meet upcoming demand." According to Pharm-Olam's Poland Country Manaer, Dr. Janusz Rupinski, "With a population of almost 40 million people, Poland offers rapid recruitment in most therapeutic areas. When combining the extensive population with experienced investigational staff and the efficient transfer of study supplies as an EU member state; Poland is primed for extensive growth in the clinical trial arena." Dr. Rupinski further explains, "As of September 22, 2015, there were approximately 1,150 Phase I-IV active clinical trials ongoing in Poland. Of these trials there were 396 trials registered in 2014 and 329 in 2015 to date." For more information about Pharm-Olam, please contact [email protected]. About Pharm-Olam International Group Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. For further information about Pharm-Olam, please visit www.pharm-olam.com. View source version on businesswire.com: http://www.businesswire.com/news/home/20151013006451/en/ |
